Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Recommended Offer for Anker

24 Aug 2005 12:11

Torex Retail PLC24 August 2005 Torex Retail Plc24 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR ANKER PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding Anker Shares The Board of Torex Retail Plc ("Torex Retail") announces that the offer (the"Offer") made by UBS Investment Bank on behalf of Torex Retail for Anker Plc("Anker") has today become wholly unconditional. As at 3.00 p.m. on 23 August 2005, Anker had received valid acceptances of theoffer in respect of a total of 41,177,970 Anker Shares, representingapproximately 99.02 per cent. of the existing issued share capital of Anker. As at 3.00 p.m. on 23 August 2005, valid acceptance of the Offer in relation to8,292,325 Anker Shares, representing 19.94 per cent. of the existing issuedordinary share capital of Anker, had been received electing for the basic termsof the Offer, valid acceptances of the Offer in relation 26,192,409 AnkerShares, representing approximately 62.99 per cent. of the existing issuedordinary share capital of Anker, had been received electing for additional cashunder the Mix and Match Facility and valid acceptances of the Offer in relation6,693,236 Anker Shares, representing approximately 16.10 per cent. of theexisting issued ordinary share capital of Anker, had been received electing foradditional New Torex Retail Shares under the Mix and Match Facility. Prior to the posting of the Offer Document on 22 July 2005, Torex Retail hadreceived irrevocable undertakings or letters of intent from the Anker Directorsand certain other Anker Shareholders to accept or procure the acceptance of theOffer in respect of, in aggregate, 31,347,988 Anker Shares, representingapproximately 75.4 per cent. of the existing issued ordinary share capital ofAnker. Included in the valid acceptances of the Offer set out above areacceptances in respect of 31,347,988 Anker Shares, representing approximately75.4 per cent. of the existing issued ordinary share capital of Anker, receivedpursuant to such irrevocable undertakings and letters of intent. Neither Torex Retail nor any persons deemed to be acting in concert with it forthe purposes of the Offer owned any Anker Shares (or rights over such shares) on29 June 2005 (being the last dealing day prior to the commencement of the Offerperiod) nor has Torex Retail nor any person deemed to be acting in concert withit for the purposes of the Offer acquired or agreed to acquire any Anker Shares(or rights over such shares) during the Offer period other than by way ofacceptances of the Offer. Compulsory Acquisition and cancellation of listing As described in the Offer Document, as and when Torex Retail receivesacceptances under the Offer in respect of, and/or otherwise acquired 90 percent. or more of the Anker Shares to which the Offer related, Torex Retailintends to exercise its rights pursuant to the provisions of sections 428 to430F of the Companies Act 1985 to acquire compulsorily Anker Shares in respectof which acceptances have not been received. Accordingly, Torex Retail is today issuing notices under s.429 of the CompaniesAct 1985 to Anker Shareholders who have not yet accepted the Offer that it nowintends to exercise its rights to acquire compulsorily all of those Anker Sharesstill outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice, althoughthe Mix and Match Facility is now closed. Notice has also been sent to the Board of Anker requesting that the AnkerDirectors make an application to AIM for cancellation of the admission totrading of Anker Shares on AIM. It is expected that such cancellation willbecome effective after 20 clear business days following this announcement on the20 September 2005. For Anker Shares held in certificated form, Forms of Acceptance should becompleted, signed and returned in accordance with instructions set out in theOffer Document and in the Form of Acceptance, so as to be received as soon aspossible. For Anker Shares held in uncertificated form, an Electronic Acceptanceshould be made in accordance with instructions set out in the Offer Document sothat the TTE Instruction settles as soon as possible. Settlement of consideration Settlement of consideration to which any Anker Shareholder is entitled will beeffected: (i) in the case of acceptances received (complete in all respects) by23 August 2005 within 7 days of this date; or (ii) in the case of acceptancesreceived (complete in all respects) after 23 August 2005 but while the Offerremains open, within 7 days of such receipt. Terms defined in the offer document dated 22 July 2005 (the "Offer Document")shall, unless the context requires otherwise, have the same meanings in thisannouncement. EnquiriesTorex Retail Plc Telephone: 01295 753313Richard Thompson / Nigel Horn UBS Investment Bank Telephone: 0207 567 8000Ben Robertson / Jackie Lee This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.